These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 11603418)
1. Spironolactone in severe heart failure: enhances efficacy of diuretic + ACE inhibitor combinations. Prescrire Int; 2000 Oct; 9(49):158-9. PubMed ID: 11603418 [TBL] [Abstract][Full Text] [Related]
2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option. Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075 [TBL] [Abstract][Full Text] [Related]
3. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too. Prescrire Int; 2006 Apr; 15(82):46-9. PubMed ID: 16604728 [TBL] [Abstract][Full Text] [Related]
4. [Cardiac insufficiency: what treatment? what dose? For which patients? Converting enzyme inhibitors and diuretics]. Komajda M Arch Mal Coeur Vaiss; 2000 Feb; 93 Spec No 2():13-6. PubMed ID: 10830083 [TBL] [Abstract][Full Text] [Related]
5. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil. Saito M; Takada M; Hirooka K; Isobe F; Yasumura Y J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294 [TBL] [Abstract][Full Text] [Related]
6. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure. Bauersachs J; Fraccarollo D Minerva Cardioangiol; 2003 Apr; 51(2):155-64. PubMed ID: 12783071 [TBL] [Abstract][Full Text] [Related]
7. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019 [TBL] [Abstract][Full Text] [Related]
8. New strategies for treatment of heart failure with aldosterone antagonists and the risk of hyperkalaemia. Cruz CS; Cruz LS; Domingues GS; Souza CA Expert Opin Drug Saf; 2005 Jul; 4(4):677-88. PubMed ID: 16011447 [TBL] [Abstract][Full Text] [Related]
9. Spironolactone for heart failure. Med Lett Drugs Ther; 1999 Sep; 41(1061):81-2. PubMed ID: 10505071 [No Abstract] [Full Text] [Related]
10. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol; 1996 Oct; 78(8):902-7. PubMed ID: 8888663 [TBL] [Abstract][Full Text] [Related]
11. Combined effects of low-dose spironolactone and captopril therapy in a rat model of genetic hypertrophic cardiomyopathy. de Resende MM; Kriegel AJ; Greene AS J Cardiovasc Pharmacol; 2006 Dec; 48(6):265-73. PubMed ID: 17204904 [TBL] [Abstract][Full Text] [Related]
12. Influence of combined angiotensin-converting enzyme inhibitors and spironolactone on serum K+, Mg 2+, and Na+ concentrations in small dogs with degenerative mitral valve disease. Thomason JD; Rockwell JE; Fallaw TK; Calvert CA J Vet Cardiol; 2007 Nov; 9(2):103-8. PubMed ID: 17983885 [TBL] [Abstract][Full Text] [Related]
13. Kalemia during combined therapy with an angiotensin converting enzyme inhibitor and a potassium-sparing diuretic. Mooser V; Waeber G; Bidiville J; Waeber B; Nussberger J; Brunner HR J Clin Hypertens; 1987 Dec; 3(4):510-3. PubMed ID: 2839627 [TBL] [Abstract][Full Text] [Related]
14. Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor. Ogawa S; Takeuchi K; Mori T; Nako K; Ito S Clin Exp Pharmacol Physiol; 2006; 33(5-6):477-9. PubMed ID: 16700881 [TBL] [Abstract][Full Text] [Related]
15. [Treatment of cardiac failure with angiotensin-converting enzyme inhibitors and diuretics]. Deray G; Martinez F; Jacobs C Arch Mal Coeur Vaiss; 1996 Jun; 89(6):735-40. PubMed ID: 8760660 [TBL] [Abstract][Full Text] [Related]
18. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647 [TBL] [Abstract][Full Text] [Related]
19. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Weir MR Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185 [TBL] [Abstract][Full Text] [Related]
20. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. van de Wal RM; Plokker HW; Lok DJ; Boomsma F; van der Horst FA; van Veldhuisen DJ; van Gilst WH; Voors AA Int J Cardiol; 2006 Jan; 106(3):367-72. PubMed ID: 16337046 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]